After-market trading session, Pulmatrix Inc. (NASDAQ: PULM) shares increases by 6.32 percent to $1.01. Pulmatrix stock fell -5.94% to $0.95 on Friday. PULM stock volume stayed at 1.3 million shares, which was less than the average daily volume of 1.95 million shares for the past 50 days. Last year, PULM stock fell -31.16%, and in the last week, it has moved down by -4.52%.
PULM stock has lost -32.62% over the last three months and -9.52% over the last six months. Additional information pertaining to PULM includes a current market capitalization of $56.80 million and its outstanding shares stood at 36.16 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Recent developments:
Pulmatrix develops inhaled therapies, developed using Pulmatrix’s patented iSPERSE technology, to address serious pulmonary diseases. There are several treatments PULM has in its pipeline, including treatments for serious lung diseases such as allergic bronchopulmonary aspergillosis (“ABPA”) and chronic obstructive pulmonary disease (“COPD”), as well as for neurological conditions.
Read More
Pulmatrix held a webinar last month on Friday, April 23, 2021 that covered the topic of PUR3100—Pulmatrix’s orally inhaled dihydroergotamine (DHE) therapy for acute migraines.
- Key opinion leaders including Stewart Tepper, MD, F.A.H.S., Geisel School of Medicine at Dartmouth, and Stephen Silberstein M.D., F.A.C.P., Thomas Jefferson University, presented on the webinar.
- Tepper spoke about how healthcare has evolved and unmet medical needs in treating patients with acute migraine.
- A new generation of DHE therapies is currently in the work, and Dr. Silberstein discussed the possibilities.
What’s next?
Pulmatrix (PULM) CEO, Ted Raad, also provided a corporate overview, including the focus of PUR3100, a dry powder synthesis of DHE to treat acute migraines. PULM’s PUR3100 is currently in preclinical trials as a migraine orally-inhaled therapy with Phase I and Phase II results expected by 2022.
